Financial Performance - The company's operating revenue for the reporting period was 67,363,245.41 yuan, a decrease of 21.84% compared to the same period last year [2] - The net profit attributable to shareholders was 1,180,325.54 yuan, down 75.06% year-on-year [2] - The basic earnings per share decreased by 75.00% to 0.01 yuan, while diluted earnings per share dropped by 100.00% to 0.00 yuan [2] - The total assets at the end of the reporting period were 934,063,765.94 yuan, a decrease of 2.69% from the previous year [2] Cash Flow Analysis - The net cash flow from operating activities was 14,859,155.99 yuan, an increase of 171.73% compared to the previous period [7] - The net cash flow from investing activities was 18,597,586.88 yuan, a decrease of 34.57% year-on-year [7] - The net cash flow from financing activities was -40,384,964.10 yuan, a significant decrease of 954.70% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings were detailed, with the largest shareholder holding 18,402,400 shares [9] - The company has a significant relationship between major shareholders, indicating potential influence on corporate governance [9] Changes in Financial Indicators - The company experienced a 49.04% decrease in cash and cash equivalents due to investments in structured deposits and wealth management products [6] - The accounts receivable increased, leading to a 245.94% rise in credit impairment losses [7] - The company reported a 90.80% decrease in other non-current assets, primarily due to a reduction in equipment prepayments [6]

Core Viewpoint - Suzhou Su Shi Testing Group (stock code: 300416) reported a 10.57% increase in operating revenue for Q3 2025 compared to the same period last year, but net profit attributable to shareholders decreased by 9.43% [2][19]. Financial Data Summary Main Financial Data and Indicators - Operating revenue for the current period reached CNY 541.03 million, up 10.57% year-on-year, while total revenue from the beginning of the year to the report date was CNY 1.53 billion, an increase of 8.95% [2]. - Net profit attributable to shareholders was CNY 39.55 million, down 9.43%, with a year-to-date net profit of CNY 156.84 million, up 7.14% [2]. - Basic and diluted earnings per share were both CNY 0.0778, reflecting a decrease of 9.43% [2]. - Total assets at the end of the reporting period were CNY 5.11 billion, a 1.43% increase from the previous year [2]. Non-Recurring Gains and Losses - Non-recurring gains and losses included a loss from the disposal of non-current assets of CNY -660,045.31 and government subsidies of CNY 6.02 million [4]. Changes in Major Accounting Data and Financial Indicators - Accounts receivable decreased by 32.70% due to reduced customer use of bill settlements [7]. - Short-term loans increased by 11.07% to CNY 891.96 million, primarily to supplement working capital [7]. - The company's cash flow from operating activities showed a net decrease of 24.71% to CNY 119.78 million [2][9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 41,960, with the largest shareholder, Suzhou Testing Instrument General Factory, holding 31.93% of shares [10][11]. Cash Flow Summary - The net cash flow from financing activities was -CNY 40.04 million, an improvement of 42.11% compared to the previous year [9][24]. - The net increase in cash and cash equivalents was -CNY 145.77 million, a 33.90% improvement from the previous year [9][24].

√适用□不适用 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，北京必创科技（证券代码：300667 ） 发布《 2025年三季度报告 》。报告详细内容如下： 一、主要财务数据 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √ 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 期增减 | | 年同期增减 | | 营业收入(元) | 159, 464, 459. 77 | -3.32% | 470,877,958.36 | -9.21% | | 归属于上市公司股东的净利 | -1.968, 506. 76 | 68. 80% | -11.974.053.00 | -218. 10% | | 润(元) | | | | | | 归属于上市公司股东的扣除 非经常性损益的净利润 | -4.275.725.81 | 39. 25% | -16.576.504.92 | -94. 68% | | (元 ...

Core Viewpoint - The Shanghai Institute of Optics and Fine Mechanics (SIOM) has announced multiple government procurement intentions for scientific instruments, with a total budget of 4.48 billion yuan, indicating significant investment in optical and laser technology research and development [1][2]. Procurement Intentions - SIOM has released procurement intentions for 48 items of scientific instruments, with a total budget of 2.66 billion yuan, including large-aperture pulse compression gratings, lasers, weak energy meters, single-shot picosecond signal-to-noise ratio meters, and repetition frequency signal-to-noise ratio measurement instruments, expected to be procured by October 2025 [2][6]. Instrument Descriptions - **Single-shot Picosecond Signal-to-Noise Ratio Meter**: A high-precision optical measurement instrument designed to measure the signal-to-noise ratio of ultra-short laser pulses (picosecond level), crucial for evaluating laser pulse quality in ultra-short and ultra-strong laser systems [3]. - **Repetition Frequency Signal-to-Noise Ratio Measurement Instrument**: An electronic measurement device used to assess the relative strength of signals and noise in repetitive frequency working modes, important for applications in radar, laser ranging, and communication systems [4]. Detailed Procurement List - The procurement list includes various optical components and modules, such as: - Optical element modules with a budget of 1 billion yuan [7]. - Large-aperture pulse compression gratings with a budget of 5 billion yuan [8]. - High-stability lasers and other advanced optical systems, indicating a focus on enhancing laser technology capabilities [7][8]. Institutional Background - SIOM, established in 1964, is the largest and earliest research institution in laser science and technology in China, focusing on major foundational and applied research in modern optics and large-scale laser engineering technology [9]. - The institute has achieved significant milestones, including the development of the "Shenguang II" high-power laser device and the world's first space-based cold atomic clock, showcasing its leadership in the field [9][10].

摘要 ： 近日，重庆交通大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统 计出7项仪器设备采购意向，预算总额达8655万元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 重庆交通大学发布 7 项仪器设备采购意向，预算总额达 8 6 5 5万 元，涉及 1 0 0 kN 柔 性 微机控制电子万能试验机 、 2 5 0 kN微机控制电子万能试验机 、 3 0 0 kN微机控制电子万能试验 机 、高低温 核 磁 共 振 仪 、 非 饱和土动三轴仪、光学接触角测量 仪 等 ， 预 计 采 购 时 间 为 2 0 2 5 年 4~1 0 月。 部分采购仪器简介： 高低温核磁共振仪 核磁共振仪（NMR）是一种利用原子核自旋特性进行物质结构分析和成像的高端科学仪器。高 低温核磁共振仪特指具有温度控制功能的核磁共振设备，能够根据实验需求在特定温度范围内 进行测量。 电子万能试验机 电子万能试验机是一种基于电子技术、计算机控制及高精度传感器的高精度材料力学性能测试 设备，主要用于金属、非金属及复合材料的拉伸、压缩、弯曲、剪 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 四方光电（证券代码：688665） 发布《 2025年三季度报告 》。报告详细内容如下： 第一节 重要提示 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法 律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 | 稀释每股收益(元/股) | 0.23 | 15.00 | 1.07 | 75.41 | | --- | --- | --- | --- | --- | | 加权平均净资产收益率 | 2.09 | 增加 0.02 个 | 9.92 | 增加 3.64 个百 | | (%) | | 百分点 | | 分点 | | 研发投入合计 | 31.974.900.44 | 4.93 | 90.111.836.25 | 15.68 | | 研发投入占营业收入的 比例(%) | 14.95 | 减少 0.26个 百 ...

如果你的实验日志里，也藏着这些 "卡脖子" 的难题，那这门《化学方法验证实操技能提升特 训营》，就是帮你跳出 "反复试错" 的救命课 —— 从检出限计算到不确定度评估，全流程教你 "一次做对"，学完直接能用在实验室！ 为什么这门课能帮你解决问题？ 不是枯燥讲标准，而是带着你 "落地实操"，连新手都能快速上手！ 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 还在为这些问题熬夜改数据？ 检出限算 3 遍仍怕错，被领导打回重做？ 线 性 范围设 错 导 致 样 品 全 报 废 ，白忙 3 天？回收率不达标、基 质 干 扰 搞 不 定 ， 项 目 卡 壳 半 个 月？ 不确定度评估对着标准书发呆，根本无从下手？ 1 . 学了就能用，不做 "纸上谈兵" 案例够真实 覆盖色谱、光谱、常规理化三大类常用方法，每个知识点都配实验室真实案例，比如 "食品中 重金属检测的回收率优化" "环境水样中有机物的基质干扰消除"，教你照搬就能解决问题； 基质有方案 针对食品、环境、医药等不同样品基质的特殊要求， "怎么调整参数、避开坑"，比如油脂类样 品如何处理才能 ...

Core Insights - The article discusses the recent announcement by the Chinese Academy of Sciences Precision Measurement Science and Technology Innovation Research Institute regarding the procurement of 23 items of scientific instruments, with a total budget of 124 million yuan [1][2]. Procurement Overview - The procurement includes advanced instruments such as the NMRAVANCENEO600MHz wide cavity control system, an 800M high-field spectrometer with ultra-low temperature solid magic angle spinning (MAS) system, and a near-zero field magnetic resonance low-temperature optical magnetic control system [2][4]. - The expected procurement timeline is set for May to October 2025 [2]. Detailed Procurement List - The procurement list includes: - NMRAVANCENEO600MHz wide cavity control system with a budget of 40 million yuan [4]. - 800M high-field spectrometer ultra-low temperature MAS system with a budget of 55 million yuan [5]. - Near-zero field magnetic resonance low-temperature optical magnetic control system with a budget of 41.7 million yuan [6]. - Underwater positioning testing multi-beam depth measurement system with a budget of 26.6 million yuan [7]. Technical Specifications - The NMRAVANCENEO600MHz system features a 12.5ns time resolution and supports multiple independent temperature control channels [4]. - The 800M high-field spectrometer is designed for enhanced sensitivity and operates within a temperature range of -20°C to 60°C [5]. - The near-zero field magnetic resonance system includes a multi-channel ultra-low frequency probe and an intelligent non-magnetic sample introduction device [6]. Research and Development Focus - The article highlights the focus on developing advanced technologies for precision measurement and magnetic resonance imaging, which are critical for scientific research and applications [2][6].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪粉e r们，今天是高薪精品仪器职位专辑 哦！ 仪器精英，热招职位 Ho t r e c r u itme n t p o siti o n s 磐诺 销售工程师 江苏-8k-12k ·13薪 任职要求： 具有一定理工科背景（分析化学、化工、检验检疫、仪器设备、电子电路、环境工程、食品科学等相关 专业优先）；具有良好的语言表达、沟通及组织及协调能力；品貌端正，性格外向，良好的社会人际关系以及团队协 作精神，普通话标准；有实验室销售工作经验或色谱仪器使用经验者优先。 莱伯泰科 ICPMS高级应用工程师 北京-20k-30k ·12薪 任 职要求 ： 支持ICPMS仪器的应用工作，全面推进应用方案开发和解决客户提出的应用问题；配合销售做ICPMS 仪器的售前支持；负责合作伙伴的销售培训，并帮助团队提升ICPMS的销售能力；支持所负责区域的市场活动：展 会、讲座等；负责调研并收集ICPMS的客户建议和客户问题，反馈给相关的产品经理；完成上级主管安排的相关事 务。 岛津 销售代表 台州-面议 ...

Core Viewpoint - The company reported strong performance in Q3 2025, with revenue, profit, and cash flow exceeding market expectations, driven by robust growth in the bioprocessing segment and better-than-expected revenue from Cepheid's respiratory business [2][3]. Financial Performance - Total revenue for Q3 reached $6.1 billion, a 4.5% increase from $5.798 billion in Q3 2024; Non-GAAP core revenue grew by 3.0% [3]. - Net profit attributable to common shareholders was $908 million, up 11.0% year-over-year, and a significant 63.6% increase from $555 million in Q2 2025; diluted EPS (GAAP) was $1.27, a 13.4% increase from $1.12 [3]. - Operating cash flow was $1.662 billion, a 9.8% year-over-year increase; Non-GAAP free cash flow reached $1.37 billion, up 11.8% from $1.226 billion [3]. Cost and Profit Structure - Q3 sales cost was $2.53 billion, a 5.6% increase, which was lower than revenue growth; gross margin was 58.2%, remaining stable compared to 58.7% in the previous year [4]. - Selling, general, and administrative expenses decreased by 3.4% to $1.991 billion, while R&D expenses slightly declined by 1.3% to $378 million, indicating effective cost control [4]. Segment Performance - Biotech segment grew by 9.0%, driven by strong demand in bioprocessing; Life Sciences segment saw a modest 0.5% growth, impacted by currency fluctuations; Diagnostics segment revenue increased by 4.0%, supported by Cepheid's respiratory business [6]. - Year-to-date revenue reached $17.73 billion, a 2.5% increase compared to the same period in 2024; Biotech segment led with a 7.5% revenue growth, while Life Sciences segment experienced a 1.0% decline [6]. Full-Year Outlook - The company maintains its full-year Non-GAAP diluted EPS guidance in the range of $7.70 to $7.80, expecting low single-digit growth in Non-GAAP core revenue [7]. - For Q4, core revenue is anticipated to achieve low single-digit growth, with the Biotech segment expected to grow around 5% and Life Sciences segment projected to decline slightly [7]. Management Insights - The CEO highlighted the encouraging Q3 performance, attributing it to effective execution of the Danaher Business System and ongoing growth in bioprocessing, alongside Cepheid's strong revenue [9]. - The company continues to focus on innovation, enhancing operational efficiency, and addressing key challenges in global healthcare [9].